Search Results - "CANETE, Adela"

Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study by Gaspar, Nathalie, Venkatramani, Rajkumar, Hecker-Nolting, Stefanie, Melcon, Soledad Gallego, Locatelli, Franco, Bautista, Francisco, Longhi, Alessandra, Lervat, Cyril, Entz-Werle, Natacha, Casanova, Michela, Aerts, Isabelle, Strauss, Sandra J, Thebaud, Estelle, Morland, Bruce, Nieto, Adela Cañete, Marec-Berard, Perrine, Gambart, Marion, Rossig, Claudia, Okpara, Chinyere E, He, Cixin, Dutta, Lea, Campbell-Hewson, Quentin

“…Tyrosine kinase inhibitors have shown activity in osteosarcoma and might enhance the efficacy of chemotherapy. We aimed to determine the recommended phase 2…”
Get full text

Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project by Campbell, Kevin, Shyr, Derek, Bagatell, Rochelle, Fischer, Matthias, Nakagawara, Akira, Nieto, Adela Canete, Brodeur, Garrett M., Matthay, Katherine K., London, Wendy B., DuBois, Steven G.

“…Background MYCN amplification (MYCN‐A) is an established adverse prognostic factor in neuroblastoma. The extent to which the prognostic impact of MYCN‐A…”
Get full text

Scaling up and implementing the digital Survivorship Passport tool in routine clinical care – The European multidisciplinary PanCareSurPass project by Filbert, Anna-Liesa, Kremer, Leontien, Ladenstein, Ruth, Chronaki, Catherine, Degelsegger-Márquez, Alexander, van der Pal, Heleen, Bardi, Edit, Uyttebroeck, Anne, Langer, Thorsten, Muraca, Monica, Nieto, Adela Cañete, Rascon, Jelena, Bagnasco, Francesca, Beyer, Stefan, te Dorsthorst, Jeroen, Essiaf, Samira, Galan, Antonio Orduña, Kienesberger, Anita, O’Brien, Kylie, Palau, Marisa Correcher, Pluijm, Saskia M.F., di Profio, Sonia, Saraceno, Davide, Schneider, Carina, Schreier, Günter, Trinkūnas, Justas, Zamberlan, Igor, Grabow, Desiree, Haupt, Riccardo

“…Childhood cancer survivors (CCS), of whom there are about 500,000 living in Europe, are at an increased risk of developing health problems [1–6] and require…”
Get full text

Risk stratification of high‐risk metastatic neuroblastoma: A report from the HR‐NBL‐1/SIOPEN study by Morgenstern, Daniel A., Pötschger, Ulrike, Moreno, Lucas, Papadakis, Vassilios, Owens, Cormac, Ash, Shifra, Pasqualini, Claudia, Luksch, Roberto, Garaventa, Alberto, Canete, Adela, Elliot, Martin, Wieczorek, Aleksandra, Laureys, Geneviève, Kogner, Per, Malis, Josef, Ruud, Ellen, Beck‐Popovic, Maja, Schleiermacher, Gudrun, Valteau‐Couanet, Dominique, Ladenstein, Ruth

“…Background Risk stratification is crucial to treatment decision‐making in neuroblastoma. This study aimed to explore factors present at diagnosis affecting…”
Get full text

Excellent Outcome With Reduced Treatment in Infants With Nonmetastatic and Unresectable Neuroblastoma Without MYCN Amplification: Results of the Prospective INES 99.1 by RUBIE, Hervé, DE BERNARDI, Bruno, BROCK, Penelope, CASTEL, Victoria, VALTEAU-COUANET, Dominique, HOLMES, Keith, DI CATALDO, Andrea, BRICHARD, Bénédicte, MOSSERI, Véronique, MARQUEZ, Catalina, PLANTAZ, Dominique, BONI, Luca, GERRARD, Mary, MICHON, Jean, CANETE, Adela, LADENSTEIN, Ruth, COUTURIER, Jérôme, AMBROS, Peter, MUNZER, Caroline, PEARSON, Andrew D. J, GARAVENTA, Alberto

“…To evaluate the efficacy of low-dose chemotherapy in infants with nonmetastatic and unresectable neuroblastoma (NB) without MYCN amplification. Infants with…”
Get full text

Poor Survival for Infants With MYCN-Amplified Metastatic Neuroblastoma Despite Intensified Treatment: The International Society of Paediatric Oncology European Neuroblastoma Experience by CANETE, Adela, GERRARD, Mary, DE BERNARDI, Bruno, PEARSON, Andrew J, MICHON, Jean, RUBIE, Hervé, CASTEL, Victoria, DI CATALDO, Andrea, MUNZER, Caroline, LADENSTEIN, Ruth, BRICHARD, Bénédicte, BERMUDEZ, José D, COUTURIER, Jerome

“…To report the results of a prospective, nonrandomized European study on infants with neuroblastoma and MYCN gene amplification. Infants with neuroblastoma…”
Get full text

European recommendations for short-term surveillance of health problems in childhood, adolescent and young adult cancer survivors from the end of treatment to 5 years after diagnosis: a PanCare guideline by de Beijer, Ismay A. E., Skinner, Roderick, Haupt, Riccardo, Grabow, Desiree, Bardi, Edit, Beccaria, Andrea, Nieto, Adela Cañete, Essiaf, Samira, Filbert, Anna-Liesa, Gsell, Hannah, Kienesberger, Anita, Langer, Thorsten, McColgan, Patricia, Muraca, Monica, Rascon, Jelena, Tallone, Ramona, Tomasikova, Zuzana, Uyttebroeck, Anne, Kremer, Leontien C. M., van der Pal, Helena J. H., Mulder, Renée L., Niehoff, Dorothea, Walz, Diana, Erdmann, Friederike, Spix, Claudia, Lightwood, Simone, Bagnasco, Francesca, Cavalca, Giacomo, Oberti, Sara, Nicolas, Brigitte, Ladenstein, Ruth, Düster, Vanessa, van Helvoirt, Maria, Lemiere, Jurgen, Renard, Marleen, Michiels, An, Kock-Schoppenhauer, Ann-Kristin, Hildebrand, Lea, Jahnke, Anke Neumann Anne-Katrin, Trinkūnas, Justas, Ciesiūnienė, Audronė, Ragauskas, Paulius, Guill, Julia Balaguer, Alcañiz, Maria Teresa Tormo, Galan, Antonio Orduña, Palau, Marisa Correcher, Beltrán, Lucas Cervero, Tamarit, Vicente Pons, Saraceno, Davide, Berti, Alessandra, Contino, Carlo, Thomopulos, Nikos, Stabile, Giulia, Tomassi, Maria Franca, Zamberlan, Igor, Nichel, Barbara, Schreier, Günter, Hayn, Dieter, Kreiner, Karl, Beyer, Stefan, Chronaki, Catherine, Cangioli, Giorgio, Charalambous, Eliana, Degelsegger-Márquez, Alexander, Gredinger, Gerald, Trunner, Kathrin, Trauner, Florian, Laschkolnig, Anja, Kremer, Leontien, van der Pal, Heleen, Pluijm, Saskia, van den Oever, Selina, de Beijer, Ismay, Trollip, Jessica, Hardijzer, Emma, Hartogh, Jaap den, Dorsthorst, Jeroen te, Sciberras, William, Schneider, Carina

“…Abstract Purpose Childhood, adolescent and young adult (CAYA) cancer survivors require ongoing surveillance for health problems from the end of cancer…”
Get full text

Factors Influencing Implementation of the Survivorship Passport: The IT Perspective by Chronaki, Catherine, Charalambous, Eliana, Cangioli, Giorgio, Schreier, Günter, van den Oever, Selina, van der Pal, Helena, Kremer, Leontien, Uyttebroeck, Anne, Van den Bosch, Bart, Trinkunas, Justas, Rascon, Jelena, Ladenstein, Ruth, Düster, Vanessa, Bardi, Edit, Walz, Diana, Filbert, Anna-Liesa, Grabow, Desiree, Langer, Thorsten, Cañete Nieto, Adela, Orduña Galán, Antonio J, Correcher Palau, Marisa, Cavalca, Giacomo, Haupt, Riccardo

“…Compared to the general population, childhood cancer survivors represent a vulnerable population as they are at increased risk of developing health problems,…”
Get more information

Hypermethylation of apoptotic genes as independent prognostic factor in neuroblastoma disease by Grau, Elena, Martinez, Francisco, Orellana, Carmen, Canete, Adela, Yañez, Yania, Oltra, Silvestre, Noguera, Rosa, Hernandez, Miguel, Bermúdez, Jose D., Castel, Victoria

“…Neuroblastoma (NB) is an embryonal tumour of neuroectodermal cells, and its prognosis is based on patient age at diagnosis, tumour stage and MYCN…”
Get full text

Vitronectin as a molecular player of the tumor microenvironment in neuroblastoma by Burgos-Panadero, Rebeca, Noguera, Inmaculada, Cañete, Adela, Navarro, Samuel, Noguera, Rosa

“…Vitronectin is a multifunctional glycoprotein known in several human tumors for its adhesive role in processes such as cell growth, angiogenesis and…”
Get full text

Barriers and facilitators to the implementation of a new European eHealth solution (SurPass v2.0): the PanCareSurPass Open Space study by de Beijer, Ismay A E, Hardijzer, Emma C, Haupt, Riccardo, Grabow, Desiree, Balaguer, Julia, Bardi, Edit, Cañete Nieto, Adela, Ciesiūniene, Audronė, Düster, Vanessa, Filbert, Anna-Liesa, Gsell, Hannah, Kapitančukė, Monika, Ladenstein, Ruth, Langer, Thorsten, Muraca, Monica, van den Oever, Selina R, Prikken, Sofie, Rascon, Jelena, Tormo, Maria Teresa, Uyttebroeck, Anne, Vercruysse, Gertrui, van der Pal, Helena J H, Kremer, Leontien C M, Pluijm, Saskia M F

“…To identify barriers and facilitators for implementing the Survivorship Passport (SurPass) v2.0 in six long-term follow-up (LTFU) care centres in Europe…”
Get full text

Delving into the clinical impact of NETs in pediatric cancer by Benavent, Nuria, Cañete, Adela, Argilés, Bienvenida, Juan-Ribelles, Antonio, Bonanad, Santiago, Oto, Julia, Medina, Pilar

“…Pediatric cancer, a complex and heterogeneous group of diseases, continues to challenge medical research and treatment strategies. Despite advances in…”
Get full text

Deletion of 11q in Neuroblastomas Drives Sensitivity to PARP Inhibition by Sanmartín, Elena, Muñoz, Lisandra, Piqueras, Marta, Sirerol, J Antoni, Berlanga, Pablo, Cañete, Adela, Castel, Victoria, Font de Mora, Jaime

“…Despite advances in multimodal therapy, neuroblastomas with hemizygous deletion in chromosome 11q (20%-30%) undergo consecutive recurrences with poor outcome…”
Get full text

Advances in emerging drugs for the treatment of neuroblastoma by Berlanga, Pablo, Cañete, Adela, Castel, Victoria

“…Neuroblastoma is the most common solid extracranial tumor of childhood. Outcome for children with high-risk neuroblastoma remains suboptimal. More than half of…”
Get more information

Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma by Grill, Jacques, Massimino, Maura, Bouffet, Eric, Azizi, Amedeo A, McCowage, Geoffrey, Cañete, Adela, Saran, Frank, Le Deley, Marie-Cécile, Varlet, Pascale, Morgan, Paul S, Jaspan, Tim, Jones, Chris, Giangaspero, Felice, Smith, Helen, Garcia, Josep, Elze, Markus C, Rousseau, Raphaël F, Abrey, Lauren, Hargrave, Darren, Vassal, Gilles

“…Purpose Bevacizumab (BEV) is approved in more than 60 countries for use in adults with recurrent glioblastoma. We evaluated the addition of BEV to radiotherapy…”
Get full text

Staging childhood cancers in Europe: Application of the Toronto stage principles for neuroblastoma and Wilms tumour. The JARC pilot study by Gatta, Gemma, Botta, Laura, Capocaccia, Riccardo, Cañete, Adela, Pritchard‐Jones, Kathy

“…Background The ‘Toronto consensus principles and guidelines’ (TG) provided paediatric‐specific staging system affordable by population‐based cancer registries…”
Get full text

Interoperability Architecture for a Paediatric Oncology European Reference Network by Nitzlnader, Michael, Canete Nieto, Adela, Ribelles, Antonio Juan, Brunmair, Barbara, Ladenstein, Ruth, Schreier, Günter

“…With the Directive 2011/24/EU on patients' rights in cross-border healthcare and the related delegated decisions, the European Commission defined a legal…”
Get more information

Vitronectin Levels in the Plasma of Neuroblastoma Patients and Culture Media of 3D Models: A Prognostic Circulating Biomarker? by López-Carrasco, Amparo, Vieco-Martí, Isaac, Granados-Aparici, Sofía, Acevedo-León, Delia, Estañ-Capell, Nuria, Portugal, Raquel, Huerta-Aragonés, Jorge, Cañete, Adela, Navarro, Samuel, Noguera, Rosa

“…Vitronectin is a glycoprotein present in plasma and the extracellular matrix that is implicated in cell migration. The high amount of vitronectin found in…”
Get full text

Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study by Casanova, Michela, Bautista, Francisco, Campbell-Hewson, Quentin, Makin, Guy, Marshall, Lynley V., Verschuur, Arnauld C., Cañete Nieto, Adela, Corradini, Nadège, Ploeger, Bart A., Brennan, Barbara J., Mueller, Udo, Zebger-Gong, Hong, Chung, John W., Geoerger, Birgit

“…Abstract Purpose: This phase Ib study defined the safety, MTD, and recommended phase II dose (RP2D) of regorafenib combined with vincristine and irinotecan…”
Get full text

High Oct4 expression: implications in the pathogenesis of neuroblastic tumours by Monferrer, Ezequiel, Burgos-Panadero, Rebeca, Blanquer-Maceiras, Maite, Cañete, Adela, Navarro, Samuel, Noguera, Rosa

“…Neuroblastic tumours (NBTs) are paediatric solid tumours derived from embryonic neural crest cells which harbour their own cancer stem cells (CSC). There is…”
Get full text